Experience with Dalbavancin Use in Various Gram-positive Infections within Aberdeen Royal Infirmary OPAT Service

Author:

McSorley James C.1,Reyes Darshini2,Tonna Ivan2,Bateman Vhairi2

Affiliation:

1. University of Aberdeen

2. NHS Grampian, Aberdeen Royal Infirmary

Abstract

Abstract Purpose: dalbavancin, approved in 2014 for Gram-positive acute bacterial skin and skin structure infections (ABSSSI), has pharmacokinetics enabling treatment with one or two doses. Dalbavancin might be useful in outpatient parenteral antibiotic therapy (OPAT) of deep-seated infections otherwise requiring inpatient admission. We documented our experience with pragmatic dalbavancin use to assess its effectiveness for varied indications, on and off label, as primary or sequential consolidation therapy. Methods: patients prescribed dalbavancin between 1st December 2021 and 1st October 2022 were screened for demographics of age, sex, Charlson comorbidity index (CCI), allergies, pathogens, doses of dalbavancin, other antibiotics administered and surgery. Where available, infection markers were recorded. Primary outcome was cure at end of treatment. Secondary outcomes were adverse events and for treatment failures, response to salvage antibiotics. Results: Sixty seven percent of patients were cured. Cure rates by indication were 93 % for ABSSSI, 100 % for bacteraemia, 90 % for acute osteomyelitis, 0 % for chronic osteomyelitis, 75 % for native joint septic arthritis and 33 % for prosthetic joint infection. Most bone and joint infections not cured did not have source control and the goal of treatment was suppressive. Successful suppression rates were greater at 48 % for chronic osteomyelitis and 66 % for prosthetic joint infections. Adverse events occurred in 14 of 102 patients. Conclusion: This report adds to clinical experience with dalbavancin for off label indications whilst further validating its role in ABSSSI. Dalbavancin as primary therapy in deep seated infections merits investigation in formal clinical trials.

Publisher

Research Square Platform LLC

Reference53 articles.

1. Treatment of Gram–positive infections in critically ill patients. BMC Infect Dis. 2014 Nov 28; 14:92. doi: 10.1186/1471–2334–14–92. PMID: 25431211; PMCID: PMC4289239;Vazquez–Guillamet C

2. TongSY,DavisJS,EichenbergerE,HollandTL,FowlerVGJr.Staphylococcusaureusinfections:epidemiology,pathophysiology,clinicalmanifestations,andmanagement.ClinMicrobiolRev.2015Jul;28(3):603–61.doi:10.1128/CMR.00134–14.PMID:26016486;PMCID:PMC4451395.

3. Chronic osteomyelitis: what the surgeon needs to know. EFORT Open Rev. 2017 Mar 13;1(5):128–135. doi: 10.1302/2058–5241.1.000017. PMID: 28461939; PMCID: PMC5367612;Panteli M

4. LebeauxD,GhigoJM,BeloinC.Biofilm–relatedinfections:bridgingthegapbetweenclinicalmanagementandfundamentalaspectsofrecalcitrancetowardantibiotics.MicrobiolMolBiolRev.2014Sep;78(3):510–43.doi:10.1128/MMBR.00013–14.PMID:25184564;PMCID:PMC4187679.

5. Fernández–Hidalgo N, Lebeaux D. Understanding biofilm formation in intravascular device–related infections. Intensive Care Med. 2017 Mar;43(3):443–446. doi: 10.1007/s00134–016–4480–7. Epub 2016 Aug 6. PMID: 27497588;Beloin C

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3